Role of bendamustine in the treatment of chronic lymphocytic leukemia

OncoTargets and Therapy

Volumn 2, Issue , 2009, Pages 43-49

  Jamshed, Saad ^a   Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Bendamustine; Chemotherapy; Chronic lymphocytic leukemia

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; FLUDARABINE; LENALIDOMIDE; MITOXANTRONE; RITUXIMAB;

ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PNEUMONIA; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SEPSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77953437123     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Ries LAG, Melbert D, Krapcho M, et al. National cancer institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2005/, based on november 2007 SEER data submission, posted to the SEER website, 2008.
2. Cheson BD, Bennett JM, Grever M, et al. National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997. (Pubitemid 26189840)
3. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the minnie pearl cancer research network. J Clin Oncol. 2003;21:1746-1751. (Pubitemid 46638587)
4. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153-2164. (Pubitemid 32366969)
5. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001;98:1326-1331.
6. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165-2170. (Pubitemid 32366970)
7. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975-980.
8. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from cancer and leukemia group B 9712 (CALGB 9712). Blood. 2003;101:6-14.
9. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105:49-53. (Pubitemid 40053062)
10. Hallek M, Fingerle-Rowson G, Fink A, et al. Immunochemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival of previously untreated patients with advanced chronic lymphocytic leukemia. Blood. 2008;112:p.125,325.
11. Ferrajoli A, O'Brien S, Wierda W, Keating M. Treatment of patients with CLL 70 years old and older: A single center experience of 142 pateints. Leuk Lymphoma. 2005;46 (Suppl):S95-S86.
12. Ozegowski W, Krebs D. IMET 3393, (-[1-methyl-5-bis-(β- chloräthyl)-aminobenzimidazolyl-(2)]-butter säurehydrochlorid, ein neues zytostatikum aus der reihi der benzimidazol-loste. Zbl Pharm. 1971;110:1013-1019.
13. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309-317.
14. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs. 1996;7:415-421. (Pubitemid 26249195)
15. Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E. In vitro studies with bendamustine: Enhanced activity in combination with rituximab. Semin Oncol. 2002;29:12-14. (Pubitemid 34857891)
16. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica. 2002;87:33-43. (Pubitemid 34101111)
17. Fischer K, Stilgenbauer S, Schweighofer CD, et al. Bendamustine in combination with rituximab for patients with relapsed chronic lymphocytic leukemia: A multicentre phase II trial of the German CLL Study Group (GCLLSG). Blood. 2008;112:p.128,330.
18. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-hodgkin's lymphoma. J Clin Oncol. 2005;23:3383-3389.
19. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-hodgkin's lymphoma. J Clin Oncol. 2008;26:4473-4479.
20. Aivado M, Schulte K, Henze L, Burger J, Finke J, Haas R. Bendamustine in the treatment of chronic lymphocytic leukemia: Results and future perspectives. Semin Oncol. 2002;29:19-22. (Pubitemid 34857893)
21. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-hodgkin's-lymphomas. J Cancer Res Clin Oncol. 2002;128:603-609. (Pubitemid 35435557)
22. Kath R, Blumenstengel K, Fricke HJ, Hoffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol. 2001;127:48-54. (Pubitemid 32128513)
23. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase I/II study of the German CLL Study Group. Haematologica. 2005;90:1357-1364. (Pubitemid 41503651)
24. Lissitchkov T, Arnaudov G, Peytchev D, Merkle K. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (binet stages B and C) requiring therapy. J Cancer Res Clin Oncol. 2006;132:99-104. (Pubitemid 41752051)
25. Niederle N, Balleisen L, Heit W, et al. Bendamustine versus fludarabine as second-line treatment for patients with chronic lymphocytic leukemia - first interim results of a randomized study. Annals of Onclogy. 2008;19:379.
26. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine versus chlorambucil as first-line treatment in B-cell chronic lymphocytic leukemia: an updated analysis from an international phase III study. Blood. 2008;112:p. 728,2091.
27. Koppler H, Heymanns J, Pandorf A, Weide R. Bendamustine plus mitoxantrone - a new effective treatment for advanced chronic lymphocytic leukaemia: Results of a phase I/II study. Leuk Lymphoma. 2004;45:911-913. (Pubitemid 38444666)
28. Weide R, Pandorf A, Heymanns J, Koppler H. Bendamustine/Mitoxantrone/ Rituximab (BMR): A very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. final results of a pilot study. Leuk Lymphoma. 2004;45:2445-2449. (Pubitemid 40081187)
29. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
30. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): A randomised controlled trial. Lancet. 2007;370:230-239. (Pubitemid 47069536)
31. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291-5297.
32. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol. 2006;24:5343-5349. (Pubitemid 46623164)
33. Heerema NA, Byrd JC, Andritsos LA, et al. Clinical activity of flavopiridol in relapsed and refractory chronic lymphocytic leukemia (CLL) with high-risk cytogenetic abnormalities: Updated data on 89 patients. Blood. 2007;110:p.914,3107.